Forefront Wealth Management Inc. Acquires New Stake in Novo Nordisk A/S $NVO

Forefront Wealth Management Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 25,451 shares of the company’s stock, valued at approximately $1,295,000.

A number of other hedge funds have also made changes to their positions in the stock. Quotient Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares during the period. Beacon Financial Group increased its stake in shares of Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after acquiring an additional 178 shares during the period. True North Advisors LLC increased its stake in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after acquiring an additional 199 shares during the period. Kavar Capital Partners Group LLC increased its stake in shares of Novo Nordisk A/S by 0.6% during the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after acquiring an additional 200 shares during the period. Finally, SeaBridge Investment Advisors LLC grew its position in Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on NVO. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Short interest fell sharply in March (about a 19% drop vs. mid‑March), lowering near‑term bearish pressure and reducing potential short‑covering risk. (Source: recent short‑interest report)
• Positive Sentiment: EMA cleared an update allowing Wegovy injections to be delivered at up to 30°C for 48 hours, which should improve distribution flexibility and lower logistics costs in Europe — a modest operational tailwind. Wegovy EMA approval
• Positive Sentiment: Wegovy’s oral formulation appears to be expanding the obesity treatment market by drawing new patients (not just switching injection users), supporting longer‑term demand potential for Novo’s GLP‑1 franchise. CNBC short on Wegovy pill
• Neutral Sentiment: Positive buy‑and‑hold coverage and listings naming Novo as a top growth stock provide long‑term investor support but do not address near‑term competitive or pricing issues. Yahoo piece on growth thesis
• Neutral Sentiment: Novo Holdings (the controlling shareholder) is adding investments outside pharma (e.g., superconductors), which is a corporate/portfolio move with limited direct impact on Novo Nordisk’s operational outlook. Novo Holdings investment
• Negative Sentiment: Eli Lilly launched its once‑daily oral GLP‑1 (Foundayo) broadly in the U.S., increasing competitive pressure on Novo’s market share and pricing power in weight‑loss treatments. Foundayo availability
• Negative Sentiment: Reports of cheap semaglutide generics in India are eroding pricing power in key markets and could weigh on longer‑term revenue if generics expand beyond regional markets. India generics report
• Negative Sentiment: UBS and other analysts warn Q1 results (May 6) will be the first meaningful read on economics at new, lower GLP‑1 price points; coupled with a disappointing CagriSema trial and below‑consensus 2026 guidance earlier this year, this raises near‑term earnings risk. UBS pricing test note
• Negative Sentiment: Media and commentators highlight Eli Lilly pulling ahead in the obesity drug race, which can weigh on sentiment and relative valuation for Novo in the near term. 247WallSt comparison

Novo Nordisk A/S Trading Down 0.0%

Shares of NYSE:NVO opened at $37.52 on Monday. The firm has a fifty day moving average of $41.03 and a two-hundred day moving average of $48.92. The firm has a market capitalization of $167.51 billion, a P/E ratio of 10.81, a price-to-earnings-growth ratio of 8.85 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.43%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.